Navigation Links
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Date:5/30/2009

Promising Anti-cancer Activity Observed in Relapsed Patients

ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American Society of Oncology (ASCO) in Orlando, Florida. Data from a Phase 1b study and an ongoing Phase 2 clinical trial of carfilzomib in relapsed patients with advanced solid tumors demonstrate promising single-agent anti-cancer activity. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

"In these clinical studies, carfilzomib demonstrated promising activity as a highly selective and potent inhibitor of the proteasome for treatment of solid tumor patients. The compound's unique characteristics enable the drug to be well tolerated with consecutive day dosing, which in turn appears to improve anti-cancer activity. Early results among patients with late-stage or metastatic solid tumors who have failed multiple prior treatments are encouraging, with a number of patients achieving stable disease or better lasting for several months," said Peter J. Rosen, M.D., Medical Director of the Tower Cancer Research Foundation and Emeritus Professor, UCLA.

Data from the Phase 1b/2 clinical trials of relapsed solid tumor patients were presented by Dr. Rosen at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in an oral presentation titled "Phase II results of Study PX-171-007: A Phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors" (Abstract #3515).

The Phase 1b dose-escalating clinical trial enrolled patients with a variety of relapsed solid tumors established a dosing schedul
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
2. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
7. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... Medicity Institute (Medicity) has approved a treatment program entitled: ... Infection in Combination with Standard of Care (SOC) Drug ...
... will help its guests reach their well-being goals by ... cold and flu season. Beginning Sept. 1, 2010, the ... Target Pharmacy and Target Clinic locations nationwide. Continuing its ... again offering the seasonal flu vaccine at the low ...
Cached Medicine Technology:Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 2Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 3Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 4Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 5Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 6Target to Serve as Prevention HQ this Flu Season 2
(Date:7/12/2014)... Recently, Fadhits.com, a well-known wedding dress manufacturer and ... graduation dresses to its product line. In addition, the ... It wants to bring more benefits for its loyal fans. ... discounted prices, up to 72% off. , As a leader ... Its online shop is a good place for ladies who ...
(Date:7/12/2014)... July 13, 2014 Recently, iFitDress.com, one of ... selection of red evening gowns . What’s more, all ... 56% off. , The company’s senior spokesman states, “We are ... on our website is an enjoyable shopping experience. In addition ... our online store, low prices do not always mean bad ...
(Date:7/12/2014)... 2014 The Chicken Egg Production ... five years, buoyed by stable demand for industry products ... “Eggs are a relatively affordable staple for most families ... generally grows in line with the size of the ... demand for new specialty egg products with enriched qualities, ...
(Date:7/12/2014)... Passenger Information System market is estimated to grow from ... at an expected CAGR of 26.5% for the period ... in North America is well developed and network infrastructure ... the region. The growing ridership figures in public transport ... driving the North American Passenger Information System market at ...
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World Cup, ... at Sun Life Stadium in an international friendly. The World ... stars in the world of football in Colombian and Brazilian ... some of the best talent in the world in early ... team in the world according to the Fédération Internationale de ...
Breaking Medicine News(10 mins):Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3
... With Food Prices on the Rise New Tools to Help ... Personal finance expert Suze Orman,is the latest celebrity to join ... in their health. With rising food costs, many,families are economizing ... is nutrition. At about 25 cents per 8 ounce glass, ...
... Do Not Feel Knowledgeable About Their,Cancer Risks and Justifies ... and Entertain, LOS ANGELES, Sept. 29 Olympic ... and Nastia Liukin, along with Team USA,will join with ... national network,television special, Frosted Pink with a Twist, in ...
... in outcomes, but offers no concrete answers , , MONDAY, Sept. ... ZIP codes are more likely to die after surgery than ... research. , The study analyzed death rates among more than ... high-risk heart or cancer surgeries between 1999 and 2003. ...
... National initiative launched to support CMS, hospital-acquired,conditions ... Today the National Business,Coalition on Health ... Centers,for Medicare and Medicaid Services, (CMS) efforts ... for specific "Never Events" -- serious and,costly ...
... cases, unproven ,therapies, can be dangerous, experts say , , ... turn to the Internet as a source of information ... are betrayed by purveyors of so-called cancer "cures" that ... five companies were charged with making false and misleading ...
... readers of improper removal of asbestos in St. Louis that may ... The city used an unapproved "wet method" of removing asbestos fibers, ... evaporates. , ... Denver, CO (PRWEB) September 29, 2008 ...
Cached Medicine News:Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:Video: 2008 US Olympic Gymnastic Superstars Join Today's Top Music Icons for Women's Cancer Awareness Network Special, Frosted Pink with a Twist 2Health News:Video: 2008 US Olympic Gymnastic Superstars Join Today's Top Music Icons for Women's Cancer Awareness Network Special, Frosted Pink with a Twist 3Health News:Video: 2008 US Olympic Gymnastic Superstars Join Today's Top Music Icons for Women's Cancer Awareness Network Special, Frosted Pink with a Twist 4Health News:Seniors in Poor Areas More Likely to Die After Surgery 2Health News:National Business Coalition on Health Endorses New CMS 'Never Events' Policy 2Health News:National Business Coalition on Health Endorses New CMS 'Never Events' Policy 3Health News:National Business Coalition on Health Endorses New CMS 'Never Events' Policy 4Health News:Scams and Shams That Prey on Cancer Patients 2Health News:Scams and Shams That Prey on Cancer Patients 3Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 3
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: